- Home
- CNTA vs CPRX Comparison
CNTA vs CPRX Comparison
Compare CNTA & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- CPRX
- Stock Information
- Founded
- CNTA 2020
- CPRX 2002
- Country
- CNTA United Kingdom
- CPRX United States
- Employees
- CNTA N/A
- CPRX N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CNTA Health Care
- CPRX Health Care
- Exchange
- CNTA Nasdaq
- CPRX Nasdaq
- Market Cap
- CNTA 2.3B
- CPRX 2.5B
- IPO Year
- CNTA 2021
- CPRX 2006
- Fundamental
- Price
- CNTA $17.16
- CPRX $21.27
- Analyst Decision
- CNTA Strong Buy
- CPRX Strong Buy
- Analyst Count
- CNTA 7
- CPRX 7
- Target Price
- CNTA $23.71
- CPRX $31.14
- AVG Volume (30 Days)
- CNTA 705.7K
- CPRX 916.5K
- Earning Date
- CNTA 11-12-2024
- CPRX 11-06-2024
- Dividend Yield
- CNTA N/A
- CPRX N/A
- EPS Growth
- CNTA N/A
- CPRX 114.68
- EPS
- CNTA N/A
- CPRX 1.18
- Revenue
- CNTA $6,853,000.00
- CPRX $460,482,000.00
- Revenue This Year
- CNTA N/A
- CPRX $23.98
- Revenue Next Year
- CNTA N/A
- CPRX $18.27
- P/E Ratio
- CNTA N/A
- CPRX $18.05
- Revenue Growth
- CNTA N/A
- CPRX 32.17
- 52 Week Low
- CNTA $6.65
- CPRX $13.12
- 52 Week High
- CNTA $18.97
- CPRX $24.27
- Technical
- Relative Strength Index (RSI)
- CNTA 50.89
- CPRX 45.60
- Support Level
- CNTA $16.02
- CPRX $20.93
- Resistance Level
- CNTA $18.12
- CPRX $22.67
- Average True Range (ATR)
- CNTA 1.08
- CPRX 0.66
- MACD
- CNTA -0.08
- CPRX -0.07
- Stochastic Oscillator
- CNTA 41.42
- CPRX 19.54
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.